Results 131 to 140 of about 1,807,537 (411)

Inhibition of acyl‐CoA synthetase long‐chain isozymes decreases multiple myeloma cell proliferation and causes mitochondrial dysfunction

Molecular Oncology, EarlyView.
Triacsin C inhibition of the acyl‐CoA synthetase long chain (ACSL) family decreases multiple myeloma cell survival, proliferation, mitochondrial respiration, and membrane potential. Made with Biorender.com. Multiple myeloma (MM) is an incurable cancer of plasma cells with a 5‐year survival rate of 59%.
Connor S. Murphy, Heather Fairfield, Victoria E. DeMambro, Samaa Fadel, Carlos A. Gartner, Michelle Karam, Christian Potts, Princess Rodriguez, Ya‐Wei Qiang, Habib Hamidi, Xiangnan Guan, Calvin P. H. Vary, Michaela R. Reagan   +12 more
wiley   +1 more source

Characterisation of the androgen regulation of glycine N-methyltransferase in prostate cancer cells [PDF]

, 2013
The development and growth of prostate cancer is dependent on androgens; thus, the identification of androgen-regulated genes in prostate cancer cells is vital for defining the mechanisms of prostate cancer development and progression and developing new ...
Brinkmann, Chen, Ciara O'Hanlon-Brown, Claessens, Cleutjens, Cook, Cunha, Dai, Devos, Feldman, Greg N Brooke, Gregory, Haelens, Haelens, Ham, Heinlein, Jonathan Waxman, Laki Buluwela, Lin, Lu, Luke, Lund, Massie, Massie, Ngan, Nird  , Rennie, Rowling, Shang, Shen, Silvia Ottaviani, Simak Ali, Song, Sreekumar, Verrijdt, Wang, Yu   +36 more
core   +1 more source

TRPM4 contributes to cell death in prostate cancer tumor spheroids, and to extravasation and metastasis in a zebrafish xenograft model system

Molecular Oncology, EarlyView.
Transient receptor potential melastatin‐4 (TRPM4) is overexpressed in prostate cancer (PCa). Knockout of TRPM4 resulted in reduced PCa tumor spheroid size and decreased PCa tumor spheroid outgrowth. In addition, lack of TRPM4 increased cell death in PCa tumor spheroids.
Florian Bochen, Saurav Subedi, Federico La Manna, Sofia Jarrin, Irida Papapostolou, Marianna Kruithof‐de Julio, Christine Peinelt   +6 more
wiley   +1 more source

The incidence of prostate cancer in Iran: Results of a population-based cancer registry [PDF]

, 2007
Background: Little is known about the epidemiology of prostate cancer in Iranian men. We carried out an active prostate cancer surveillance program in five provinces of Iran.
Alimohammadian, M., Babai, M., Darvish-Moghadam, S., Fakheri, H., Ghorbani, A., Mansour-Ghanaei, F., Mohagheghi, M.A., Nooraie, M., Sadjadi, A., Semnani, S., Zahedi, M.J.   +10 more
core  

Cell‐free DNA aneuploidy score as a dynamic early response marker in prostate cancer

Molecular Oncology, EarlyView.
mFast‐SeqS‐based genome‐wide aneuploidy scores are concordant with aneuploidy scores obtained by whole genome sequencing from tumor tissue and can predict response to ARSI treatment at baseline and, at an early time point, to ARSI and taxanes. This assay can be easily performed at low cost and requires little input of cfDNA. Cell‐free circulating tumor
Khrystany T. Isebia, Anouk C. de Jong, Lisanne F. van Dessel, Vanja de Weerd, Corine Beaufort, Jean Helmijr, José Alberto Nakauma‐González, Job van Riet, Paul Hamberg, Daniel Vis, Michiel S. van der Heijden, Nick Beije, Martijn P. Lolkema, Teoman Deger, Saskia M. Wilting, Ronald de Wit, Maurice P. H. M. Jansen, John W. M. Martens   +17 more
wiley   +1 more source

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. [PDF]

, 2016
Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer death among men in the United States. In recent years, several new agents, including cancer immunotherapies, have been approved or are currently being ...
Bander, Neil H, Beer, Tomasz M, Drake, Charles G, Fong, Lawrence, Gulley, James L, Harrelson, Stacey, Kantoff, Philip W, Madan, Ravi A, McNeel, Douglas G, Oh, William K, Peace, David J, Petrylak, Daniel P, Porterfield, Hank, Sartor, Oliver, Shore, Neal D, Slovin, Susan F, Stein, Mark N, Vieweg, Johannes   +17 more
core   +1 more source

Chemosensitization of Human Renal Cell Cancer Using Antisense Oligonucleotides Targeting the Antiapoptotic Gene Clusterin

Neoplasia: An International Journal for Oncology Research, 2001
BACKGROUND: Renal cell cancer (RCC) is a chemoresistant disease with no active chemotherapeutic agent achieving objective response rates higher than 15%.
Tobias Zellweger, Hideaki Miyake, Laura V. July, Majid Akbari, Satoshi Kiyama, Martin E. Gleave   +5 more
doaj   +1 more source

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

New England Journal of Medicine, 2015
BACKGROUND Prostate cancer is a heterogeneous disease, but current treatments are not based on molecular stratification. We hypothesized that metastatic, castration-resistant prostate cancers with DNA-repair defects would respond to poly(adenosine ...
J. Mateo, S. Carreira, S. Sandhu, S. Miranda, H. Mossop, R. Pérez-López, Daniel Nava Rodrigues, D. Robinson, A. Omlin, N. Tunariu, G. Boysen, N. Porta, P. Flohr, Alexa Gillman, I. Figueiredo, C. Paulding, G. Seed, Suneil Jain, C. Ralph, A. Protheroe, S. Hussain, Robert J. Jones, T. Elliott, U. McGovern, D. Bianchini, J. Goodall, Z. Zafeiriou, C. Williamson, R. Ferraldeschi, R. Riisnaes, Bernardette Ebbs, Gemma Fowler, D. Roda, W. Yuan, Yi-Mi Wu, Xuhong Cao, R. Brough, H. Pemberton, R. A’Hern, A. Swain, L. Kunju, R. Eeles, G. Attard, C. Lord, A. Ashworth, M. Rubin, K. Knudsen, F. Feng, A. Chinnaiyan, E. Hall, J. D. de Bono   +50 more
semanticscholar   +1 more source

Quantitative ultrasound characterization and comparison of healthy and malignant prostate cells [PDF]

arXiv, 2019
Speed of sound and attenuation as a function of frequency between 2 and 18 MHz were measured and compared for a cancerous prostate cell line and a healthy prostate cell line. Speed of sound for the cancerous cells line was found to be 1521.4 $\pm$ 0.8~m/s, which was equivalent to the speed of sound for the healthy cell line of 1521.5 $\pm$ 0.6~m/s. The
arxiv  

Gold nanoshell-localized photothermal ablation of prostate tumors in a clinical pilot device study

Proceedings of the National Academy of Sciences of the United States of America, 2019
Significance Prostate cancer is the most common nonskin cancer in the United States, where approximately 1 in 9 men will be diagnosed in their lifetime.
A. Rastinehad, H. Anastos, E. Wajswol, J. Winoker, J. Sfakianos, S. Doppalapudi, M. Carrick, C. Knauer, B. Taouli, S. Lewis, A. Tewari, J. Schwartz, S. Canfield, A. George, J. West, N. Halas   +15 more
semanticscholar   +1 more source